Silver nanoparticle (AgNP) has been synthesized using adrenaline. Adrenaline readily undergoes an autoxidation reaction in an alkaline medium with the dissolved oxygen to form adrenochrome, thus behaving as a mild reducing agent for the dissolved oxygen. This reducing behavior of adrenaline when employed to reduce Ag + ions yielded a large enhancement in the intensity of absorbance in the visible region. Transmission electron microscopy (TEM) and X-ray diffraction (XRD) studies have been performed to confirm the surface morphology of AgNPs. Further, the metallic nanoparticles with size greater than 2 nm caused a strong and broad absorption band in the UV-visible spectrum called surface plasmon band or Mie resonance. The formation of AgNPs caused the large enhancement in the absorbance values with λmax at 436 nm through the excitation of the surface plasmon band. The formation of AgNPs was adopted to for the quantitative assessment of adrenaline using spectrophotometry with lower detection limit and higher precision values.
Introduction
Nanoscience has been recognized recently as a new interdisciplinary science. The term "nanoparticles" refers to the clusters of atoms aggregated in the size range of 1 -100 nm. One of the most widely used nanoparticles for spectrometric enhancement is the silver nanoparticle (AgNP) due to its useful optical and catalytic properties. [1] [2] [3] In addition to the antibacterial activities, the application of AgNPs as an analytical sensor for biological fluids has received widespread acceptance. 4 Various methods have been reported in the literature for the synthesis of AgNPs. Physical methods involve evaporation/condensation, and laser ablation also belongs to the same category. 5 Chemical methods of preparation of AgNPs involve the use of reducing agents, radiation chemicals, non-deleterious solvents, polysaccharides and microbes such as bacteria and fungus.
AgNPs have exceptional properties that make them available and important for a wide range of applications ranging from photovoltaic cells to both biological and chemical sensors due to their exceptional optical properties [6] [7] [8] and simple synthesis procedure. 9 However, the determination of pharmaceuticals with the formation of AgNPs is rarely studied using spectrophotometry. In this current work adrenaline, a hormone and neurotransmitter, has been used as a reducing agent to prepare AgNPs and simultaneously analyzed for its content in marketed formulation through excitation of surface plasmon resonance (SPR). 10 The reaction of adrenaline and silver nitrate in the presence of NaOH results in the formation of silver nanoparticles. The formation of AgNPs is mechanically based on the reduction of silver ions (Ag + ) into metallic silver (Ag 0 ) in the presence of a reducing agent which results in the nucleation of the metallic silver and finally the agglomeration into the oligomeric clusters. In this reaction, adrenaline acts as the reducing agent and the Cetyltrimethylammonium bromide (CTAB) acts as a stabilizer that controls further agglomeration and sedimentation of the colloidal nanoparticles.
Adrenaline (also known as epinephrine) is chemically known as (R)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol ( Fig. 1) . Adrenaline was discovered by Takamine and Uenaka in 1900. 11 Increasing the heart rate and constricting the blood vessels to help dilate the air passage are important uses of this title drug. It is a hormone produced by the adrenal gland and is also a neurotransmitter used for the treatment of heart failure. 12 It is listed in the United States Pharmacopeia 13 that the nonaqueous titration method with perchloric acid having crystal violet solution as an indicator is the official method of analysis of adrenaline.
Spectrophotometric methods are adopted by many researchers as these techniques are based on UV absorption and chemical reactions. These spectrophotometric methods are advantageous over other techniques not only in terms of less time and labor consumption but also because they have excellent precision. The applications of the spectrophotometric method have become widespread and many research papers on the pharmaceutical analysis have appeared in the literature. 14, 15 Different techniques have been used in the quantitative analysis of adrenaline, including high performance liquid chromatography (HPLC). [16] [17] [18] Flow injection techniques also find application in the determination of adrenaline. 19, 20 In addition to HPLC, LC-MS has been used by many scientists to quantitate adrenaline in various matrices. 21, 22 The literature shows a number of researchers have used spectrophotometry for the quantitative analysis of adrenaline. [23] [24] [25] Although the literature includes a number of spectrophotometric methods, there is no method reported using AgNPs having CTAB as a stabilizer.
Experimental

Apparatus
The spectrophotometric measurements were carried out on a Thermo Evolution 300 UV-visible spectrophotometer with matched quartz cell. Confirmation of the drug and the forced degradation products was done using a Micromass Quattro Premier triple-quadrupole mass spectrometer fitted with an ESI source. Vacuum to the mass spectrometer was provided by an Oerlikon rotary pump; Model SOGEVAC SV40 BI (Paris, France). The highest sensitivity was obtained when the mass spectrometer was operated in positive ionization mode to get m/z 184 for adrenaline. The monitoring conditions were optimized for adrenaline. The mass spectrometric parameters selected for the detection of adrenaline were cone voltage 15 V, capillary voltage 3.0 kV, desolvation temperature 300 C and source temperature 120 C. The cone gas flow was 60 L h -1 and the desolvation was 600 L h -1 . MassLynx V4.1 software (Micromass, Manchester, Lancashire, UK) was used for data acquisition purposes.
Surface morphology of the synthesized AgNP was studied on a JEOL ultra-high resolution field emission electron microscope (Model JEM 2100F). An X-ray diffractometer (XRD) (Rigaku, Ultima IV, Germany) equipped with CuKα (λ = 1.54056 Å) radiation source operated in the θ/2θ mode in the 10 -80 (2θ) range with the step-scan of 2θ = 0.01 was used to record the XRD patterns.
Reagents and standards
In the current work all the reagents and chemicals used were of analytical reagent grade. Adrenaline and CTAB were obtained from Sigma-Aldrich, USA. Sodium hydroxide was procured from Merck Ltd., Mumbai, India. The pharmaceutical marketed formulation of adrenaline was purchased from the local market and was manufactured in Ireland by the Antigen Pharmaceutical Co.
Standard and test solution preparation
For the preparation of the standard adrenaline solution, 25 mg of adrenaline was dissolved in 50 mg of Milli-Q water and the solutions were further diluted as per the requirement for preparing various samples including the linearity samples. For the preparation of the test sample, 5 vials containing 1 mg per mL of adrenaline were dissolved in a 10 mL volumetric flask and sonicated for 1 min. This solution was further diluted as required. For the determination process, 1.0 × 10 -2 M AgNO3, 2.47 × 10 -4 M CTAB and 0.1 N NaOH solutions were used.
Proposed procedure for the determination of adrenaline
A standard solution of adrenaline equivalent to 1.0 -12 μg mL -1 was pipetted into a series of 10 mL standard volumetric flasks. To each flask, 1.0 mL of 2.47 × 10 -4 M CTAB, 1.0 mL of 1.0 × 10 -2 M AgNO3 and 1.3 mL of 0.1 N NaOH was added and made up to 25 mL. The flask was thoroughly mixed and spectrophotometric studies were performed by recording the absorbance of each flask at 240 nm. The absorbance of each sample was recorded and was plotted against the concentration to obtain the calibration curve. The determination analyses were performed at 25 ± 1 C.
Determination of adrenaline in commercial dosage form
Then, 5 vials of adrenaline injections equivalent to 5 mg adrenaline were dissolved in water in a 10 mL standard volumetric flask and sonicated for 1 min. The drug solution equivalent to 1.0 -12 μg mL -1 was pipetted out and were assayed by the developed method mentioned above. The amount of drug can be calculated from the linear regression equation or from the calibration plot.
Results and Discussion
Optimization of variables
Before proceeding to the synthesis reaction of the AgNP and its application, the optimum conditions of the synthesis must be selected. For this, the reagents used in the synthesis were checked for the optimum concentrations for the reaction to occur. The effect of the concentration of AgNO3 was investigated in the concentration range of 8.0 × 10 -5 to 4.4 × 10 -4 M and it was observed that with an increase in the concentration of AgNO3, there was an increase in the absorbance from 8.0 × 10 -5 to 3.6 × 10 -4 M; after this, the absorbance was found to be constant up to 4.4 × 10 -4 M. Therefore, 4.0 × 10 -4 M, the intermediate value of 3.6 × 10 -4 and 4.4 × 10 -4 M, was selected as the optimum value of silver nitrate (Fig. 2) . Similarly, the required concentration of NaOH was checked and it was observed that increasing the concentration of NaOH from 4.0 × 10 -4 M resulted in an increase in the absorbance, which finally became constant at 4.8 × 10 -3 M and remained as such up to 6.0 × 10 -3 M. Thus, the concentration in between the two constant absorbance points i.e. 5.2 × 10 -3 M was selected for the current investigation (Fig. 3) . During our studies, it was observed that the concentration of CTAB influences the rate of agglomeration of silver atoms (and also the shape/size i.e. the numbers of silver atoms agglomerated together) to form the nanoparticles. The concentration of the CTAB was optimized in the range of 9.8 × 10 -7 to 1.8 × 10 -5 M and it was found that there was no change in color yield or absorbance at the studied concentration.
Thus, 9.8 × 10 -6 M was selected for the determination process. However, it was observed that beyond a CTAB concentration of 1.8 × 10 -5 M, there was a decrease in the absorbance owing to the fact that surfactant (CTAB) molecule prevents the aggregation of reduced silver to form AgNPs. Therefore, for a complete reaction, each of the reagents must be present in the adequate amount as finalized after the optimization study.
Spectral studies and formation of AgNPs
Adrenaline readily undergoes an autoxidation reaction in an alkaline medium with the dissolved oxygen to form adrenochrome, thus behaving as a mild reducing agent for the dissolved oxygen. This reducing behavior of adrenaline when employed to reduce Ag + ions yielded a large enhancement in the absorbance in the visible region with λmax at 436 nm. The increase in absorbance was attributed to the formation of AgNPs. 26, 27 The Ag + ions reduced by the adrenaline molecule agglomerated into clusters to form nanoparticles. The metallic nanoparticles having a size greater than 2 nm caused a strong and broad absorption band in the UV-visible spectrum, called surface plasmon band (SPB) or Mie resonance. 28 The considerable enhancement in the absorption values due to the formation of nanoparticles makes SPB a very useful and potential tool for the biodetection of such molecules. Thus, through the formation of NPs or excitation of the surface plasmon band, the sensing and detection of even a few molecules in a biological system is achievable.
During the optimization process, it was observed that the interaction between the adrenaline and NaOH resulted in a λmax of 436 nm initially followed by a sharp decrease in the visible region. The absorbance then continued to increase in the UV-region with the new characteristic band peaking at 240 nm; this was all due to the formation of adrenochrome. There is a sharp change in color when the adrenaline is added to the solution containing CTAB, AgNO3 and NaOH in the optimized concentration, where CTAB acts as a stabilizer for AgNPs. The change in color results in the formation of a deep yellow colored solution having a characteristic band peaking at 240 nm. The increase in the intensity of the absorbance is credited to the formation of AgNPs as it is a well-known fact that the solution of silver ions/atoms is colorless. The synthesized nanoparticles were subjected to transmission electron microscopy (TEM) and X-ray diffraction (XRD) characterization. The TEM image is shown in Fig. 4 , while the XRD spectrum is shown in Fig. 5 . It is evident from the TEM image that both spherical and nonspherical particles having a size of 20 -55 nm are present.
The X-ray diffraction patterns of the AgNPs formed by reduction with adrenaline were recorded using an X-ray diffractometer (Rigaku, Ultima IV, Germany).
The diffractometer was equipped with a CuKα radiation source having the operating wavelength of λ = 1.54056 Å. It was operated (in θ/2θ mode) in the 10 -80 (2θ) range with the step-scan of 2θ = 0.01 .
The synthesized AgNPs were separated by using the HERMLE Z 36 HK, High Speed Centrifuge (manufactured by HERMLE Labortechnik GmbH, Germany) at 20000 rpm. The nanoparticles were washed with ethanol three times and centrifuged repeatedly to obtain the purified fine crystals. A few crystals were used to study the electron diffraction behavior. The studies indicated the presence of peaks at 2θ values of 37.42 , 43.64 , 63.98 and 77.05 . These peak values of 2θ correspond to (111), (200), (220) and (311) planes of silver, respectively. The XRD spectrum given in Fig. 2(a) confirms the face-centered cubic crystal structure of the nanoparticles with lattice constant of a ~4.076 Å (the reported value of a = 4.086 Å; Joint Committee on Powder Diffraction Studies File No. 4-0783). The possible mechanism for the formation of AgNP with the presence of adrenaline is presented in Scheme 1.
The comparative spectral studies were performed by relating the UV-vis spectra of the authentic sample of adrenaline with that of the blank and the complex resulting in the formation of AgNPs. During the experiments, it was observed that the real sample of adrenaline absorbs maximally at 280 nm while the blank solution achieved λmax at 298 nm. The addition of the adrenaline in the blank solution resulted in the formation of AgNPs and change in the absorption wavelength and the resulting wavelength is different from the λmax of both the drug and the blank as the new peak appears at 436 nm. The summary of the spectral studies is given in Fig. 6 .
Analytical data and method validation Method validation. Method validation in the pharmaceutical
and biopharmaceutical industries is intended to help safeguard patient safety during clinical trials and also when the drugs are released to the commercial market. It is the tool to demonstrate the suitability of the developed method for the intended purpose. During the validation of the methods, the protocol of the regulatory authorities such as ICH must be followed. The ICH guideline 29 recommends the study of specificity, accuracy and precision, linearity and range, limit of detection and limit of quantitation. However, before going into detailed method validation, the identity of the compound must be checked for confirmation that the compound being used is the required compound.
Confirmation of identity
Confirmation of identity is an important parameter to make sure that the compound used in the experiment is the target analyte. The studied compound adrenaline was confirmed using mass spectrometry. For this experiment, 12 μg mL -1 solution was directly infused into the mass detector and was operated in positive ionization mode and the spectra were obtained. The MS conditions of capillary voltage, cone voltage, source temperature and desolvation temperature were set as 3.0 kv, 15 kv, 120 C, 300 C, respectively. The spectra thus obtained show the major component having a mass to charge ratio (m/z) of 184 (Fig. 7) which confirmed the presence of adrenaline.
Preparation of degradation product and its characterization
Adrenaline was subjected to stress conditions for the preparation of degradation products. The stress conditions were acidic, basic, thermal and oxidation. At all these conditions adrenaline samples were stressed and subjected to mass spectrometric analysis to identify the major degradation product. During the investigation it was found that the acid degraded adrenaline showed the major compound having a m/z of 153, while the base degradation resulted in m/z 223. Similarly, the degradation of adrenaline by heat and oxidant formed major Scheme 1 Possible mechanism for the formation of silver nanoparticles with adrenaline. products having m/z 166 and 110, respectively.
Linearity
Linearity studies of the adrenaline estimation via the formation of AgNPs was performed at six concentration levels of 1, 2, 4, 6, 10 and 12 μg mL -1 . At each concentration level, five independent analyses were performed. The absorbance thus obtained at the specified concentration levels were plotted against the concentration of adrenaline to obtain the linear regression equation. A plot of the concentration vs. the absorbance yielded the following linear regression equation A = 0.0815 + 0.153 C where, C is the concentration of drug. The correlation coefficient was found to be 0.9984. Using the plot, other parameters such as limit of detection (LOD) and limit of quantitation (LOQ), as well as variance were also calculated. The details of the analytical data are shown in Table 1 .
Accuracy and precision
To evaluate the accuracy and the precision of the developed method, the content of adrenaline was measured at three different concentration levels i.e. 1, 6 and 12 μg mL -1 . The accuracy and precision studies were carried out using the intraday assay and the inter-day assay. In the intra-day assay, adrenaline was determined at the selected concentration within one day; while in the latter case, five independent analyses were performed for adrenaline estimated at the same concentration level for five consecutive days by the developed method. The results of the accuracy and precision studies are summarized in Table 2 . The results in the table show that the standard deviation and the recovery by the developed method are quite satisfactory and prove that the developed method is very effective for the determination of adrenaline in pharmaceutical formulations.
Validity of the proposed method
Recovery studies were performed to evaluate the validity of the proposed method. The recovery studies were performed through the standard addition method, where, a known amount of the reference drug i.e. adrenaline was spiked to the marketed formulation of adrenaline at three different concentration levels and the nominal value of adrenaline was calculated using the proposed method. The summarized study (Table 3) shows that the results obtained are reproducible with low standard deviation (SD) and relative standard deviation (RSD). Sa and Sb are the standard deviation of intercept and slope, respectively. 
LOD and LOQ
LOD and LOQ are important parameters of method validation; the two can be calculated using the following equations 
where, SD represents the standard deviation while the slope of the calibration line is denoted by b. LOD and the LOQ of the proposed method were calculated to be 0.25 and 0.75 μg mL -1 , respectively.
Robustness
The robustness study was performed to check the capacity of the developed method to remain unaffected by small but deliberate changes in the operational parameters and to get an indication about its reliability during the application of the method.
The changed parameters included: volume of 0.1 M NaOH = ± 0.2 mL; volume of 1.0 × 10 -2 M AgNO3 = ± 0.1 mL; and volume of 2.47 × 10 -4 M CTAB = 0.3 mL. To check the robustness of the developed procedure, a quality control sample containing 8 μg mL -1 adrenaline was determined using the developed procedure by varying the experimental condition in the range mentioned above. Under the changed experimental condition, the assay results of the five replicate samples show that the RSD and the recovery were found to be 1.87 and 99.33%, respectively.
Comparison with existing procedures
In our previous work we studied the kinetics of the formation of AgNPs. 31 The silver atoms or ions are not absorbed in the visible reason but upon their agglomeration into nanoparticles they change into the orange colored compound and the absorbance of this colored AgNPs changes with an increase in time. This change in color was kinetically monitored in our previous work, where, the rate of change of reaction was monitored. It was observed that the rate constant decreases with an increase in the concentration of the CTAB, while the rate constant was found to be independent of the concentration of adrenaline and AgNO3. The current work is different from the previous work in that the color optimization was performed at a fixed time and absorbance at a fixed time was used to prepare a calibration plot from which the amount of the drug can be calculated from the pharmaceutical formulations.
A similar type of reaction involving the gold nanoparticle is reported in the literature, where the assay of adrenaline was performed. 32 The detection limit for adrenaline in the reported method was found to be 2.0 × 10 -5 M, whereas in our current study the detection limit was 1.35 × 10 -6 M (2.47 × 10 -1 μg mL -1 ) which is 10 times lower than that reported previously. In addition to the above experimental advantages, the synthesis of the AgNPs is more cost effective compared to the synthesis of the gold nanoparticles. Thus, from an analytical perspective, we consider the current method to be more cost effective with a lower detection limit.
Conclusions
The proposed method exploits the property of the adrenaline to form AgNPs by autoxidation reaction in an alkaline medium. The formation of AgNPs caused a large enhancement in the absorbance values with λmax at 436 nm through the excitation of the surface plasmon band and was adopted to develop the technique for the quantitative assessment of adrenaline in pure and marketed formulations for routine quality control analysis. The developed method is very simple and highly sensitive as it can be used to estimate drug concentration as low as 0.748 μg mL -1 . The developed method involves no tedious pretreatment. The degradation product was characterized using mass spectrometry and its structure was established based on the mass to charge ratio. Thus, the method can be easily used for pharmaceutical quality control and in studies conducted at academic institutions and research laboratories. 
